NZ521257A - Factor VII or VIIa-like molecules - Google Patents

Factor VII or VIIa-like molecules

Info

Publication number
NZ521257A
NZ521257A NZ521257A NZ52125701A NZ521257A NZ 521257 A NZ521257 A NZ 521257A NZ 521257 A NZ521257 A NZ 521257A NZ 52125701 A NZ52125701 A NZ 52125701A NZ 521257 A NZ521257 A NZ 521257A
Authority
NZ
New Zealand
Prior art keywords
polypeptide
fviia
conjugates
life
amino acid
Prior art date
Application number
NZ521257A
Inventor
Kim Vilbour Andersen
Anders Hjelholt Pedersen
Claus Bornaes
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DKPA200000218 priority Critical
Priority to DKPA200001558 priority
Application filed by Maxygen Aps, Maxygen Holdings Ltd filed Critical Maxygen Aps
Priority to PCT/DK2001/000094 priority patent/WO2001058935A2/en
Publication of NZ521257A publication Critical patent/NZ521257A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6437Coagulation factor VIIa (3.4.21.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21021Coagulation factor VIIa (3.4.21.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/802Fibrinopeptides, blood-coagulation factors or derivatives

Abstract

Novel factor VII (FVII) or Factor VIIa (FVIIa) polypeptide conjugates are described as is their preparation and use in therapy, particularly for the treatment of a variety of coagulation-related disorders. These novel polypeptide conjugates comprise at least one non-polypeptide moiety covalently attached to a polypeptide. The amino acid sequence of the polypeptide differs from that of wild-type FVII or FVIIa in that at least one amino acid residue comprising an attachment group for said non-polypeptide moiety has been introduced or removed. The conjugates of the present invention have one or more improved properties as compared to commercially available FVIIa, including increased functional in vivo half-life and/or increased plasma half-life, and/or increased bioavailability and/or reduced sensitivity to proteolytic degradation.
NZ521257A 2000-02-11 2001-02-12 Factor VII or VIIa-like molecules NZ521257A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DKPA200000218 2000-02-11
DKPA200001558 2000-10-18
PCT/DK2001/000094 WO2001058935A2 (en) 2000-02-11 2001-02-12 FACTOR VII OR VIIa-LIKE MOLECULES

Publications (1)

Publication Number Publication Date
NZ521257A true NZ521257A (en) 2004-10-29

Family

ID=26068765

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ521257A NZ521257A (en) 2000-02-11 2001-02-12 Factor VII or VIIa-like molecules

Country Status (18)

Country Link
US (13) US6806063B2 (en)
EP (3) EP2319541A1 (en)
JP (2) JP2003521930A (en)
CN (1) CN100488562C (en)
AT (1) AT428445T (en)
AU (3) AU783512B2 (en)
CA (2) CA2397347C (en)
CY (1) CY1109614T1 (en)
DE (1) DE60138364D1 (en)
DK (1) DK1257295T3 (en)
ES (1) ES2325877T3 (en)
IL (2) IL150692D0 (en)
NO (1) NO20023804L (en)
NZ (1) NZ521257A (en)
PL (2) PL204285B1 (en)
PT (1) PT1257295E (en)
RU (1) RU2278123C2 (en)
WO (1) WO2001058935A2 (en)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1198565A1 (en) * 1999-07-07 2002-04-24 Maxygen Aps A method for preparing modified polypeptides
EP2319541A1 (en) * 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
CZ2003611A3 (en) 2000-09-13 2003-08-13 Novo Nordisk A/S Variants of human coagulation factor VII
AU8755001A (en) * 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
AU1802902A (en) 2000-11-09 2002-05-21 Scripps Research Inst Modified factor viia
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
ES2432967T3 (en) * 2001-03-22 2013-12-05 Novo Nordisk Health Care Ag Coagulation Factor VII derivatives
HU0500060A3 (en) * 2001-09-27 2010-01-28 Novo Nordisk Healthcare Ag Human coagulation factor vii polypeptides
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
DK2279753T3 (en) * 2001-10-10 2015-11-23 Novo Nordisk As The conversion of peptides and glycokonjugering
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
ES2490590T3 (en) 2001-11-02 2014-09-04 Novo Nordisk Health Care Ag Human coagulation factor VII polypeptides
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7125846B2 (en) 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
KR20040065278A (en) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 Liquid composition of modified factor vii polypeptides
WO2003055512A1 (en) 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
US20060229239A9 (en) * 2002-03-08 2006-10-12 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
PL373728A1 (en) * 2002-04-30 2005-09-05 Maxygen Holdings Ltd. Factor vii or viia polypeptide variants
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
DE60336555D1 (en) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylated glyco forms of factor vii
ES2363205T3 (en) * 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Pegilated factor vii glicoforms.
ES2653555T3 (en) 2002-06-21 2018-02-07 Novo Nordisk Health Care Ag Solid stabilized compositions of Factor VIIa polypeptides
ES2339393T3 (en) * 2002-09-25 2010-05-19 Novo Nordisk Health Care Ag Human coagulation factor polypeptides vii.
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
DK1549677T3 (en) * 2002-09-30 2011-07-18 Bayer Healthcare Llc FVII or FVIIa variants with increased coagulation activity
BRPI0408358A (en) 2003-03-14 2006-03-21 Neose Technologies Inc branched water-soluble polymers and their conjugates
DE602004023848D1 (en) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Of factor vii polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
AU2004241698A1 (en) * 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
JP4658041B2 (en) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Liquid composition of Factor VII polypeptide
EP1611236A1 (en) * 2003-03-18 2006-01-04 Novo Nordisk Health Care AG Method for the production of gla-residue containing serine proteases
JP2006524195A (en) * 2003-03-18 2006-10-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Liquid, aqueous pharmaceutical composition Vii factor polypeptide
KR101293503B1 (en) * 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Liquid, aqueous pharmaceutical composition of factor vii polypeptides
DE602004021099D1 (en) * 2003-03-20 2009-06-25 Bayer Healthcare Llc Fvii or fviia variants
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As Intracellular formation of peptide conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (en) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Coagulation factor VII-Fc chimeric proteins for the treatment of hemostatic diseases
AU2004240553A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
DE602004025576D1 (en) * 2003-06-19 2010-04-01 Bayer Healthcare Llc Variants of the factor vii or viia gla domain
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
JP2007501811A (en) * 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Use of galactose oxidase for selective chemical bonding of the delay molecule to the therapeutic protein of interest.
CN101870729A (en) * 2003-09-09 2010-10-27 诺和诺德医疗保健公司 Coagulation factor vii polypeptides
EP1664291B1 (en) * 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
JP2007509843A (en) * 2003-10-07 2007-04-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Hybrid molecules having a Factor VII / VIIa activity
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
WO2005054275A2 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor vii solutions to remove virus
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
CN1917861B (en) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 Stabilised compositions of factor vii polypeptides
CA2552892C (en) 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
CN103215328B (en) 2004-01-21 2016-08-03 诺和诺德医疗保健公司 Transglutaminase conjugated peptide mediated
KR100545720B1 (en) 2004-05-31 2006-01-24 메덱스젠 주식회사 Glycosylated Immunoglobulin and Immunoadhesin comprising the same
JP2008503541A (en) * 2004-06-21 2008-02-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Glycosylated split factor VII mutant
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US20090176967A1 (en) * 2004-08-02 2009-07-09 Novo Nordisk Healthcare A/G Conjugation of FVII
US8828939B2 (en) * 2004-08-17 2014-09-09 Csl Behring Gmbh Modified vitamin K dependent polypeptides
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
KR101243564B1 (en) * 2004-11-12 2013-03-27 바이엘 헬스케어 엘엘씨 Site-directed modification of fviii
AU2005318106B2 (en) 2004-12-23 2011-11-03 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest
EP2386571B1 (en) * 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
DK1898945T3 (en) * 2005-06-24 2013-03-25 Drugrecure Aps Airway administration of site-inactivated FVIIA in inflammatory conditions affecting the airways
ES2397851T3 (en) 2005-07-13 2013-03-11 Novo Nordisk Health Care Ag Host cell protein inactivation cells for the production of therapeutic proteins
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1919498A2 (en) * 2005-08-26 2008-05-14 Maxygen Holdings Ltd. Liquid factor vii composition
CN101268185B (en) 2005-09-01 2013-03-27 诺沃-诺迪斯克保健股份有限公司 Hydrophobic interaction chromatography purification of factor VII polypeptides
US20090055942A1 (en) * 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
JP2009508510A (en) * 2005-09-21 2009-03-05 ノボ ノルディスク ヘルス ケア アーゲー Human coagulation factor VII polypeptide
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8461115B2 (en) * 2006-03-16 2013-06-11 Stellaris Pharmaceuticals Aps Methods for local treatment with factor VII
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
WO2007126808A1 (en) 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
WO2007115953A1 (en) * 2006-04-07 2007-10-18 Novo Nordisk Health Care Ag Covalent factor vii-tissue factor complex
AU2007236280B2 (en) * 2006-04-11 2013-07-25 Csl Behring Gmbh Method of increasing the in vivo recovery of therapeutic polypeptides
RU2008145084A (en) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Analogues of factor ix having a long-term half-time in vivo
FR2901707B1 (en) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Recombinant or transgenic factor vii composition, each factor vii molecule having two n-glycosylation sites with defined glycannic patterns
CN101495155A (en) 2006-07-07 2009-07-29 诺沃-诺迪斯克保健股份有限公司 New protein conjugates and methods for their preparation
EP2046371A2 (en) * 2006-07-17 2009-04-15 Novo Nordisk Health Care AG Factor viia analogues with increased activity for treating thrombocytopenia
US20080242607A1 (en) * 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
FR2904558B1 (en) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "recombinant or transgenic factor vii composition, majorityally having biantennae, bisialylated and non-fucosylated glycannic forms"
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
JP2010505874A (en) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー/エス Purification method for polypeptide conjugates
US8777971B2 (en) * 2006-10-17 2014-07-15 Amj Bv Device and method for joining vessels in anastomosis
JP5876208B2 (en) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Factor VIIa- (poly) sialic acid conjugate with extended in vivo half-life
JP5448839B2 (en) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Modified clotting factor with long half-life in vivo
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
EP1972687A1 (en) * 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
RS52845B (en) 2007-04-03 2013-12-31 Biogenerix Ag Methods of treatment using glycopegylated g-csf
AU2008239586B2 (en) 2007-04-13 2013-09-26 Catalyst Biosciences, Inc. Modified factor VII polypetides and uses thereof
CN104887620A (en) 2007-05-02 2015-09-09 诺沃—诺迪斯克保健股份有限公司 High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
WO2009012502A1 (en) * 2007-07-19 2009-01-22 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Self- anchoring mems intrafascicular neural electrode
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
ES2647294T3 (en) 2007-12-27 2017-12-20 Baxalta GmbH Cell culture procedures
RU2573587C2 (en) 2008-02-27 2016-01-20 Ново Нордиск А/С Conjugated factor viii molecules
TWI465247B (en) 2008-04-11 2014-12-21 Catalyst Biosciences Inc Factor vii polypeptides that are modified and uses thereof
US20110137011A1 (en) * 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
ES2466340T3 (en) * 2008-04-24 2014-06-10 Cantab Biopharmaceuticals Patents Limited Factor IX conjugates with extended half-lives
CN102083459A (en) * 2008-05-23 2011-06-01 诺沃-诺迪斯克保健股份有限公司 Low viscosity compositions comprising a PEGylated GLA-domain containing protein
JP2011520999A (en) * 2008-05-23 2011-07-21 ノボ ノルディスク ヘルス ケア アーゲー Formulation of peg-functionalized serine protease with high concentration of aromatic preservative
JP5977945B2 (en) 2008-08-06 2016-08-24 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Conjugate proteins with long-term in vivo efficacy
RU2539797C2 (en) 2009-01-22 2015-01-27 Ново Нордиск Хелс Кеа Аг Human growth hormone derivative highly resistant to proteolytic degradation, method for preparing this derivative, using it, method of treating, and pharmaceutical composition
BR112012004094A2 (en) 2009-08-24 2016-03-08 Amunix Operating Inc coagulation factor vii compositions and methods for making and using them
CN108530543A (en) 2009-02-03 2018-09-14 阿穆尼克斯运营公司 Extend recombinant polypeptide and includes the composition of the extension recombinant polypeptide
NO2440239T3 (en) 2009-06-09 2018-02-10
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
CN102573920B (en) 2009-07-27 2015-01-14 利普森技术有限公司 Glycopolysialylation of non-blood coagulation proteins
US8945897B2 (en) 2010-07-26 2015-02-03 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
PL2459224T3 (en) 2009-07-27 2017-08-31 Baxalta GmbH Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TWI537006B (en) * 2009-07-27 2016-06-11 Baxalta Inc Coagulation protein conjugate
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
WO2011018515A1 (en) 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX338357B (en) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP6143297B2 (en) * 2010-06-04 2017-06-07 チウムバイオ・カンパニー・リミテッドTiumBio Co., Ltd. Fusion protein having factor VII activity
TWI557135B (en) 2010-11-03 2016-11-11 Catalyst Biosciences Inc The modified factor IX Polypeptide and uses thereof
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
JP6108630B2 (en) * 2011-10-06 2017-04-05 ハンミ サイエンス カンパニー リミテッドHanmi Science Co.,Ltd. Blood coagulation factor VII and VIIa derivatives, conjugates and complexes containing them, and uses thereof
SI2822577T1 (en) 2012-02-15 2019-07-31 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
SG10201606783RA (en) 2012-02-15 2016-10-28 Amunix Operating Inc Factor viii compositions and methods of making and using same
JP2015512927A (en) * 2012-04-16 2015-04-30 カンタブ バイオファーマシューティカルズ パテンツ リミテッド Optimized subcutaneous therapy
US20150307865A1 (en) * 2012-10-15 2015-10-29 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
US20150259665A1 (en) 2012-10-15 2015-09-17 Novo Nordisk Health Care Ag Factor vii conjugates
SG10201710593UA (en) 2012-12-24 2018-02-27 Bayer Healthcare Llc Short-acting factor vii polypeptides
EP3058066A1 (en) 2013-10-15 2016-08-24 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
RU2633588C2 (en) * 2015-11-03 2017-10-13 Евгений Федорович Чередников Method for endoscopic treatment of ulcerous gastroduodenal bleeding

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4470461A (en) 1982-09-30 1984-09-11 Phillips Petroleum Company Organic nitro compounds as cosurfactants in enhanced oil recovery processes
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
AT93541T (en) 1985-07-03 1993-09-15 Genencor Int Hybrid polypeptides and methods for their preparation.
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
AU6543286A (en) 1985-10-25 1987-05-19 Zymogenetics Inc. Method of using bar1 for secreting foreign proteins
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
DK122686D0 (en) 1986-03-17 1986-03-17 Novo Industri As Production of proteins
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
EP0296413A2 (en) 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrid protein C and method for its preparation
DK323587D0 (en) 1987-06-25 1987-06-25 Novo Industri As protein
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
JPH0246296A (en) 1988-08-09 1990-02-15 Hoechst Japan Ltd Hybrid protein c and production thereof
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
JP2928287B2 (en) * 1988-09-29 1999-08-03 協和醗酵工業株式会社 Novel polypeptide
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
US5041376A (en) 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
AT135370T (en) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemically modified granulocyte colony-causing factor
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
ES2247656T3 (en) 1989-04-19 2006-03-01 Enzon, Inc. A process for forming a modified polypeptide comprising a polypeptide and polyalkylene oxide.
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DK0400472T3 (en) 1989-05-27 1996-05-13 Sumitomo Pharma A process for preparing polyethylene glycol derivatives and modified protein
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US4973317A (en) 1989-07-14 1990-11-27 Bobrove Arthur M Automatic sheath protection of hypodermic needle
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
WO1991011519A1 (en) 1990-01-26 1991-08-08 Immuno Aktiengesellschaft Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
JP3330932B2 (en) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Anticoagulant protein
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
US5492821A (en) 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
DE69127829D1 (en) 1990-11-26 1997-11-06 Genetics Inst Expression of PACE in host cells and methods of use thereof
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
DE4113487C1 (en) 1991-04-25 1992-11-05 Fleischgrosshandel Hans-Werner & Bernd Meixner Gmbh, 6301 Wettenberg, De
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ZA9303926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
IL104734D0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
DK38293D0 (en) 1993-03-31 1993-03-31 Novo Nordisk As Production of proteins
US5871384A (en) * 1993-04-20 1999-02-16 Kichijo; Hiroshi Block assembly and devices formed thereby
JPH0720127A (en) * 1993-05-07 1995-01-24 Eisai Co Ltd Method and reagent for measuring various pivka
WO1994027631A1 (en) 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
KR960705579A (en) 1993-11-10 1996-11-08 에릭에스. 딕커 An improved interferon-polymer conjugate (Improved interferon polymer conjugates)
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
DE4343591A1 (en) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh A method for evolutionary design and synthesis of functional polymers on the basis of mold elements and shape codes
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
AU2826495A (en) 1994-06-02 1996-01-04 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
WO1996000787A1 (en) 1994-06-30 1996-01-11 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE4437604A1 (en) 1994-10-21 1996-04-25 Basf Ag Conjugates of a poly or oligopeptide and a low molecular weight lipophilic compound
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU5893696A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE69620766T2 (en) 1995-08-11 2004-11-18 Novozymes A/S A process for preparing polypeptidabkömmlingen
DE19531637A1 (en) 1995-08-28 1997-03-06 Immuno Ag A pharmaceutical composition for the treatment of Blutgerinnungsstörugnen, processes for making them and their use
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP0964702B1 (en) 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
JP2001523949A (en) * 1996-11-08 2001-11-27 オクラホマ メディカル リサーチ ファウンデーション Modified protein c and methods of use thereof
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
JP2001527387A (en) 1997-01-24 2001-12-25 ノボ ノルディスク アクティーゼルスカブ Synthetic leader peptide sequence
JP2001508783A (en) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Peg Act
CA2279986A1 (en) * 1997-02-06 1998-08-13 Claus Von Der Osten Polypeptide-polymer conjugates having added and/or removed attachment groups
AU7266898A (en) 1997-04-30 1998-11-24 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
JP4011124B2 (en) 1997-06-06 2007-11-21 協和醗酵工業株式会社 Chemically modified polypeptide
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (en) * 1997-06-20 2001-02-26 Immuno Ag A recombinant cell clone with increased stability in serum and protein-free medium and method for obtaining the stable cell clone
IL133974D0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
AT454161T (en) 1997-07-18 2010-01-15 Novo Nordisk Healthcare Ag Use of fviia or fviiai for the treatment of endothelial malfunction or inhibition of the angiogenesis
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP4574007B2 (en) 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム Polyol-IFN-beta complex
AT408613B (en) 1998-06-17 2002-01-25 Immuno Ag Pharmaceutical factor vii preparation
NZ511291A (en) 1998-10-30 2003-08-29 Novozymes As A method for selecting a protein variant that has reduced immunogenicity as compared with the parent or wild-type protein
ES2289824T3 (en) 1998-10-30 2008-02-01 Novozymes A/S Glycosilated proteins with reduced allergenicity.
WO2000028065A1 (en) 1998-11-06 2000-05-18 Novo Nordisk A/S Method for the production of fvii
EP2253704B1 (en) 1999-01-19 2015-08-19 Codexis Mayflower Holdings, LLC Oligonucleotide mediated nucleic acid recombination
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6432826B1 (en) * 1999-11-29 2002-08-13 Applied Materials, Inc. Planarized Cu cleaning for reduced defects
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
AT485371T (en) 2000-05-03 2010-11-15 Novo Nordisk Healthcare Ag Variants of the human coagulation factor vii
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
AU8755001A (en) 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
CZ2003611A3 (en) * 2000-09-13 2003-08-13 Novo Nordisk A/S Variants of human coagulation factor VII
HU0301245A3 (en) * 2000-10-02 2005-12-28 Novo Nordisk Healthcare Ag Tmethod for the production of vitamin k-dependent proteins
AU1802902A (en) 2000-11-09 2002-05-21 Scripps Research Inst Modified factor viia
PL373728A1 (en) 2002-04-30 2005-09-05 Maxygen Holdings Ltd. Factor vii or viia polypeptide variants
DK1549677T3 (en) 2002-09-30 2011-07-18 Bayer Healthcare Llc FVII or FVIIa variants with increased coagulation activity
DE602004021099D1 (en) 2003-03-20 2009-06-25 Bayer Healthcare Llc Fvii or fviia variants
DE602004025576D1 (en) 2003-06-19 2010-04-01 Bayer Healthcare Llc Variants of the factor vii or viia gla domain

Also Published As

Publication number Publication date
PL362856A1 (en) 2004-11-02
US20120171765A1 (en) 2012-07-05
US7598056B2 (en) 2009-10-06
PL204285B1 (en) 2009-12-31
CA2397347A1 (en) 2001-08-16
US6806063B2 (en) 2004-10-19
US20060019336A1 (en) 2006-01-26
RU2002124129A (en) 2004-03-20
US20030096338A1 (en) 2003-05-22
IL150692D0 (en) 2003-02-12
DE60138364D1 (en) 2009-05-28
CN100488562C (en) 2009-05-20
JP2003521930A (en) 2003-07-22
US20060252690A1 (en) 2006-11-09
IL199497A (en) 2013-08-29
US8084591B2 (en) 2011-12-27
AU783512B2 (en) 2005-11-03
US7442524B2 (en) 2008-10-28
JP4509846B2 (en) 2010-07-21
EP1982732A2 (en) 2008-10-22
US20070243588A1 (en) 2007-10-18
PL206148B1 (en) 2010-07-30
AU2006200448A1 (en) 2006-03-02
DK1257295T3 (en) 2009-08-10
CA2739933A1 (en) 2001-08-16
CN1400910A (en) 2003-03-05
NO20023804D0 (en) 2002-08-09
US7511024B2 (en) 2009-03-31
US20060240524A1 (en) 2006-10-26
AU3153501A (en) 2001-08-20
EP1257295B1 (en) 2009-04-15
RU2278123C2 (en) 2006-06-20
US20060258585A1 (en) 2006-11-16
US20070142280A1 (en) 2007-06-21
WO2001058935A3 (en) 2001-11-29
PT1257295E (en) 2009-07-16
IL199497D0 (en) 2011-07-31
NO20023804L (en) 2002-09-25
US20060252689A1 (en) 2006-11-09
US7427592B2 (en) 2008-09-23
CY1109614T1 (en) 2014-08-13
US7517974B2 (en) 2009-04-14
US7414022B2 (en) 2008-08-19
EP1982732A3 (en) 2011-06-08
EP2319541A1 (en) 2011-05-11
EP1257295A2 (en) 2002-11-20
US7371543B2 (en) 2008-05-13
CA2397347C (en) 2011-07-12
US7754682B2 (en) 2010-07-13
US20060252127A1 (en) 2006-11-09
WO2001058935A2 (en) 2001-08-16
JP2005270110A (en) 2005-10-06
AT428445T (en) 2009-05-15
US20090023635A1 (en) 2009-01-22
AU2010200296A1 (en) 2010-02-18
ES2325877T3 (en) 2009-09-23
AU2006200448B2 (en) 2009-11-12
US20060228782A1 (en) 2006-10-12
US20060240525A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
Jaxel et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity
Rich et al. Hydroxyethylamine analogs of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease
Radcliffe et al. Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa.
Bach et al. Human tissue factor contains thioester-linked palmitate and stearate on the cytoplasmic half-cystine
CN102741275B (en) Coagulation factor ix compositions and methods of making and using
Abboud-Jarrous et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment
Stoka et al. Lysosomal cysteine proteases: structural features and their role in apoptosis
US7771962B2 (en) CD10-activated prodrug compounds
Rioli et al. Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme
EP1144011B1 (en) Prodrug compounds and process for preparation thereof
Pierart et al. Effect of human endopeptidase 24.11 (" enkephalinase") on IL-1-induced thymocyte proliferation activity.
AU2001275525B2 (en) Tripeptide prodrug compounds
KR100379351B1 (en) The novel peptides
Hadari et al. A ubiquitin C-terminal isopeptidase that acts on polyubiquitin chains. Role in protein degradation.
ES2262264T3 (en) Protease for activating clotting factor VII.
Yao et al. Expression of prostate‐specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non‐polyglutamated folate, folic acid
AU739028B2 (en) Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US8632771B2 (en) High molecular weight derivatives of vitamin K-dependent polypeptides
Vacca et al. L-687,908, a potent hydroxyethylene containing HIV protease inhibitor
TW474924B (en) Substituted oxadiazole and its pharmaceutical compositions useful as inhibitors of human neutrophil elastase
Grune et al. Breakdown of oxidized proteins as a part of secondary antioxidant defenses in mammalian cells
Nägler et al. Human cathepsin X: A novel cysteine protease of the papain family with a very short proregion and unique insertions 1
TW577888B (en) CCR5 modulators
Sorsa et al. A trypsin‐like protease from Bacteroides gingivalis: partial purification and characterization
Srivastava et al. Differential Catalytic Efficiency of Allelic Variants of Human GlutathioneS-Transferase Pi in Catalyzing the Glutathione Conjugation of Thiotepa

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
ASS Change of ownership

Owner name: MAXYGEN HOLDINGS LTD., KY

Free format text: OLD OWNER(S): MAXYGEN APS; MAXYGEN HOLDINGS LTD

RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: BAYER HEALTHCARE LLC, US

Free format text: OLD OWNER(S): MAXYGEN HOLDINGS LTD.

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 12 FEB 2021 BY COMPUTER PACKAGES INC

Effective date: 20140228